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Marek’s disease (MD) is an economically significant disease in chickens that is caused by the highly oncogenic Marek’s disease
virus (MDV). A major unanswered question is the mechanism of MDV-induced tumor formation. Meq, a bZIP transcription
factor discovered in the 1990s, is critically involved in viral oncogenicity, but only a few of its host target genes have been de-
scribed, impeding our understanding of MDV-induced tumorigenesis. Using chromatin immunoprecipitation-sequencing
(ChIP-seq) and microarray analysis, a high-confidence list of Meq binding sites in the chicken genome and a global transcrip-
tome of Meq-responsive genes were generated. Meq binding sites were found to be enriched in the promoter regions of upregu-
lated genes but not in those of downregulated genes. ChIP-seq was also performed for c-Jun, a known heterodimeric partner of
Meq. The close location of binding sites of Meq and c-Jun was noted, suggesting cooperativity between these two factors in mod-
ulating transcription. Pathway analysis indicated that Meq transcriptionally regulates many genes that are part of several signal-
ing pathways including the extracellular signal-regulated kinase /mitogen-activated protein kinase (ERK/MAPK), Jak-STAT, and
ErbB pathways, which are critical for oncogenesis and/or include signaling mediators involved in apoptosis. Meq activates onco-
genic signaling cascades by transcriptionally activating major kinases in the ERK/MAPK pathway and simultaneously repressing
phosphatases, as verified using inhibitors of MEK and ERK1/2 in a cell proliferation assay. This study provides significant in-
sights into the mechanistic basis of Meq-dependent cell transformation.
Marek’s disease (MD), which is caused by the highly onco-genic alphaherpesvirus Marek’s disease virus (MDV), is one
of the most economically significant diseases affecting poultry (1).
Currently, the main strategy to control MD is vaccination (2, 3).
Although current MD vaccines reduce the incidence of tumor
formation, they do not confer protection against MDV infection
and replication or prevent horizontal spread of infection. Also,
despite the widespread use of MD vaccines, field strains of MDV
continue to evolve with increased virulence in vaccinated flocks
(4, 5). Concern regarding MD is further enhanced by the unpre-
dictable and spontaneous vaccine breaks that can result in devas-
tating losses to poultry farms (6). Worldwide annual losses from
MD due to carcass condemnation and reduced egg production
exceed $2 billion (7). The cost of MD may be even larger since this
figure has not been revised to reflect new disease outbreaks or
MDV-induced immunosuppression. The inability to obtain com-
plete control necessitates a better understanding of MDV-host
interactions, not only to elucidate the events in pathogenesis but
also to develop strategies to combat infection.
One of the major unanswered questions in the pathogenesis of
MD is the mechanism underlying tumorigenesis (8). Among sev-
eral MDV genes, oncogenic properties are attributed primarily to
Meq (9). Meq is uniquely expressed in oncogenic serotypes of
MDV (10), and recombinant MDVs lacking Meq displayed no
oncogenicity in chickens (11) while retaining their ability to rep-
licate. Furthermore, knockdown of Meq using small interfering
RNA (siRNA) resulted in reduced colony formation in MSB-1, an
MDV-transformed cell line (12). In addition, analysis of MDV
tumors and transformed cells revealed consistent expression of
Meq as a latent and oncogenic component of MDV (11, 13).
Meq belongs to the bZIP family of transcription factors (TFs),
which are characterized by having an N-terminal basic DNA bind-
ing domain adjacent to a leucine zipper (9). Meq has been shown
to homodimerize with itself or form heterodimers with other
bZIP proteins, though the most stable heterodimers were found to
be with c-Jun (13, 14). Meq has been shown to bind to both viral
and chicken genomes and to regulate gene expression (8, 15). A
limited number of genes regulated by Meq such as JTAP-1, JAC,
and HB-EGF, which belong to the v-Jun transforming pathway,
have been described (13, 16). However, a global understanding of
the role of Meq in regulating the host gene expression thereby
resulting in cellular transformation is lacking.
Our major objective in this study was to gain a comprehensive
understanding of host genes that are directly regulated by Meq.
Identification of the binding sites of Meq and the corresponding
Meq-responsive genes would provide valuable information re-
garding the biologic pathways influenced by Meq. In addition to
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characterizing Meq-responsive genes, we also aim to analyze genes
that are coregulated by Meq and c-Jun. Using a virus-free, spon-
taneously immortalized chicken embryo fibroblast cell line (17)
stably transfected with Meq as a model system (16), we employed
both chromatin immunoprecipitation followed by high-through-
put sequencing (ChIP-seq) and transcriptome profiling. The re-
sulting list of Meq-regulated genes has been integrated with their
proximal Meq binding sites revealing biological pathways, includ-
ing that of MAPK, whose effect on cell proliferation was further
validated. Our results indicate that Meq controls critical transcrip-
tional programs that promote transformation through both pos-
itive and negative gene regulation.
MATERIALS AND METHODS
Cell culture. DF-1, a chicken embryo fibroblast cell line (17), and Meq-
DF-1 clone 5G (16), DF-1 stably expressing Meq driven by the cytomeg-
alovirus (CMV) promoter, were cultured in Lebowitz’s L-15 and McCoy
5A media with 15% inactivated fetal bovine serum and 100 U of penicillin
per ml and maintained at 37°C.
ChIP-seq. Meq-DF-1 cells (107) were cross-linked with 1% formalde-
hyde and incubated for 10 min at 37°C. After briefly washing the cells
twice with ice-cold phosphate-buffered saline (PBS) containing a protease
inhibitor cocktail (Cell Signaling Technology, Danvers, MA), ChIP was
performed using the chromatin immunoprecipitation assay kit protocol
according to the manufacturer’s instructions (Upstate Biotechnology,
Lake Placid, NY). Briefly, cells were lysed using the provided lysis buffer
and sonicated to yield 50- to 200-bp chromatin fragments, followed by
overnight incubation at 4°C with agarose-salmon sperm DNA for pre-
clearing to avoid nonspecific background. The supernatant fraction was
collected from the pelleted agarose by brief centrifugation, followed by
incubation overnight with 5 g of antibody at 4°C. The antibodies used
were anti-Meq polyclonal antibody (a kind gift from Lucy Lee), anti-c-Jun
antibody (Upstate Biotechnology), or rabbit IgG (Cell Signaling Technol-
ogy). The immune complexes were pulled down using salmon sperm
DNA-protein A agarose beads and then pelleted by brief centrifugation.
The samples were then washed and the immune complexes eluted. Cross-
linking was reversed by addition of 5 M NaCl to a final concentration of
0.3 M to the eluted sample and incubated in a 65°C water bath for 4 h.
After proteinase K digestion, the DNA was recovered by phenol-chloro-
form extraction. DNA was quantified using a Nanodrop 1000 (Thermo
Scientific, Wilmington, DE). The relative enrichment was determined by
quantitative PCR (qPCR) using ABI 7500 (Applied Biosystems, Foster
City, CA) and Power SYBR green Master mix (Applied Biosystems) with
the following parameters: 95°C for 10 min followed by 40 cycles of 95°C
for 15 s and 60°C for 1 min. The primers used for the ChIP assay are listed
in Table S1 in the supplemental material. The fluorescence was expressed
as threshold cycle (CT) values. The data are expressed as percent input,
calculated as 2(CT input  CT Meq antibody), where DNA before immunopre-
cipitation was used as input DNA. Replicates from each sample were sub-
jected to high-throughput sequencing at the Michigan State University
Research Technology Support Facility (MSU RTSF [www.rtsf.msu.edu])
using the Illumina Genome Analyzer II (San Diego, CA) platform. Bowtie
(18) was employed to map the validated sequences to the chicken genome
(version galGal3) using standard options to filter out extremely short
reads and ambiguous nucleotides.
Analysis of ChIP-seq data. ChIP-seq data were analyzed using the
peak calling software QuEST (19). Peaks with high confidence were de-
fined by ChIP enrichment of more than 3-fold with a 10% false-discovery
rate (FDR). For computational motif prediction, DNA sequences of 200
bp in length (100 bp around each peak) and MEME (20, 21) were used for
investigating de novo motifs with default parameters to yield consensus
motifs in each data set.
Luciferase assays for Meq motifs. Custom reporter plasmids contain-
ing a proprietary minimal promoter region and three repeats of motif 1
(TGACTCA, AP-1 like) or motif 2 (CACACAGC, MERE-II like) up-
stream of the luciferase coding region were ordered from Genecopoeia
(Rockville, MD). Meq-DF-1 cells were plated in 96-well plates at a density
of 5,000 cells/well and transfected with 50 to 100 ng of empty vector or
luciferase constructs with motif 1 or 2, respectively. Luciferase activity was
measured with the Secrete-Pair dual luminescence assay kit (Geneco-
poeia) 48 h after transfection using a microplate luminometer (Turner
Biosystems, Sunnyvale, CA).
RNA extraction and microarray analysis. Total RNA was extracted
using the Absolutely RNA Miniprep kit (Stratagene, Santa Clara, CA). The
quality and the quantity of the RNA were verified using an Agilent Bio-
analyzer 2100 (Santa Clara, CA). High-quality RNA was labeled using
Affymetrix (Santa Clara, CA) One-Cycle Target Labeling and Control
reagents. The Affymetrix chicken and pathogen GeneChips have probe
sets to query 32,773 chicken transcripts including all 17,179 chicken uni-
genes, Ensembl-predicted genes, and reporter genes. Hybridization and
scanning were performed by the MSU RTSF.
Pathway analysis. Gene accession numbers were imported into the
Ingenuity Pathway Analysis (IPA) version 8.0 software (Mountain View,
CA) along with Chicken Affymetrix identifiers and corresponding expres-
sion values (P 0.05). The “core analysis” function included in IPA was
used to interpret data in the context of biological processes, pathways, and
networks.
Validation of microarray data by qRT-PCR. Total RNA was ex-
tracted from DF-1 and Meq-DF-1 cells using the Absolutely RNA
Miniprep kit (Stratagene). First-strand cDNA was synthesized by re-
verse transcribing 250 ng of total RNA using the Superscript III First
strand synthesis Supermix for quantitative reverse transcription-PCR
(qRT-PCR) (Invitrogen, Carlsbad, CA). The qRT-PCR mixture con-
sisted of SYBR green PCR Super Mix (Applied Biosystems) and 300
nM forward and reverse primers. The primers used for the ChIP assay
are listed in Table S2 in the supplemental material. The reactions were
performed in an ABI 7500 (Applied Biosystems) with the following
settings: 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of
60°C for 1 min and 95°C for 15 s. At the end of amplification, a disso-
ciation curve analysis was performed to confirm the presence of a
single amplification product. Each sample was run in duplicate to
obtain average CT values. For negative controls, no reverse transcrip-
tase controls were used as the template in place of single-stranded
cDNA in the qRT-PCR. Expression of each gene was normalized to the
expression of -actin, and results were compared to the data obtained
from the control group according to the 2CT method.
siRNA transfection and analysis. DF-1 and Meq-DF-1 cells were
transfected with nontargeting siRNA (NT1) or siRNA-targeting Meq
(Dharmacon, Lafayette, CO) using the TransIT-TKO transfection reagent
(Mirus, Madison, WI). Cells were harvested 48 h after transfection and
used for RNA extraction. Knockdown at the mRNA level was confirmed
by qPCR. The following primers were used for Meq: forward, 5=-AGTGC
GTTTGTTGACGGAAA-3=, and reverse, 5=-CTATATACGCCCTGCGC
AC-3=, and the qPCR conditions were the same as those described above.
Data were generated from three independent experiments.
Cell proliferation. Cell proliferation was measured by using a Cell-
Titer 96 AQueous Non-Radioactive Cell Proliferation assay (Promega,
Madison, WI) according to the manufacturer’s instructions. Briefly,
cells were plated at a density of 10,000 cells/well in 96-well microtiter
plates. After overnight incubation, the cells were switched to serum-
free medium and treated with pathway inhibitors for 24 h. PD98059
(50 M) and FR180204 (1 M) (Sigma, St. Louis, MO) were used to
inhibit MEK and ERK, respectively, based on previously published
reports (22, 23). At the end of the treatment period, a combined
MTS [3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium]-phenozine methosulfate (Promega)
solution (20 l/well) was added. After incubation for 40 min at 37°C,
the absorbance was measured at 490 nm by using an enzyme-linked
immunosorbent assay plate reader (Molecular Devices, Sunnyvale,
Genome-Wide Analysis of MDV Meq Regulation
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CA). Data were derived from two independent experiments with 4
wells in each experiment.
Statistical analysis. One-way analysis of variance (ANOVA) followed
by Fisher’s test, t test, and chi-square analysis were used as necessary. A P
value of 0.05 was used as a cutoff for statistical significance.
Microarray sequence accession number. Microarray and ChIP-seq
data have been submitted to NCBI Gene Express Omnibus (GEO) under
accession number GSE47191.
RESULTS
ChIP-seq analysis of Meq and c-Jun binding sites in the chicken
genome. To identify all the binding sites occupied by Meq
and/or c-Jun within the chicken genome, ChIP was performed
using polyclonal antibodies directed against Meq, c-Jun (the
preferred dimerization partner for Meq), or IgG (control) in
Meq-DF-1 cells followed by massively parallel sequencing of
the enriched DNA fragments. There were 23 and 21.5 million
reads enriched for Meq binding but 19.6 and 18.5 million reads
for c-Jun binding from replicates 1 and 2, respectively; our
control using nonspecific IgG antibody had 0.75 and 0.69 mil-
lion reads for the two replicates, indicating a relatively low
nonspecific background. Only those reads that uniquely
mapped to the chicken genome were used for further analysis.
Peak calling was performed using the statistical program
Quantitative Enrichment of Sequence Tags (QuEST) (19) un-
der high-stringency conditions at 10% FDR. The degree of
overlap was computed using a Python script that compared
peaks in replicates. Based on this script, we noted that there was
high overlap (85% and 80% for Meq and c-Jun, respectively)
between the two biological replicates, indicating good repro-
ducibility. For further analysis of the binding sites, the peaks
were merged and used to generate a total of 15,576 peaks for
Meq and 8,545 peaks for c-Jun. To support these findings, we
performed qPCR analysis from two independently generated
ChIP experiments using primers for 15 high-confidence bind-
ing sites from top biological networks and three negative-con-
trol regions. As shown in Fig. 1, all the 15 Meq bound sites were
significantly enriched compared to IgG controls.
The location of the binding sites relative to the transcrip-
tional start site (TSS) can provide insights into how the tran-
scription factor regulates transcription. To examine the fre-
quency distribution of Meq and c-Jun binding sites relative to
TSS, peaks located 20 kb relative to the nearest TSS were
organized into 1-kb bins. Genome-wide distance correlation
analysis revealed that about 60% and 55% of Meq and c-Jun
binding sites, respectively, were located within 2 kb of a TSS
(Fig. 2A and B). To further analyze the distribution of binding
sites within 2 kb of TSS, peaks were organized into 100-bp
bins. Meq binding sites (41% of all binding sites) peaked in the
region between 300 bp and 800 bp (Fig. 2C). Similarly,
about 44% of all c-Jun binding sites were between400 bp and
1,000 bp relative to the proximal TSS (Fig. 2D).
There were a total of 1,490 and 778 genes with binding sites
within 2 kb upstream of the nearest TSS for Meq and c-Jun, re-
spectively. In our analyses, we also identified 204 genes that have
both Meq and c-Jun binding sites in their promoter regions. To
explore the similarities in Meq and c-Jun binding sites, we ana-
lyzed binding sites within 150 bp upstream of the TSS in genes
with both Meq and c-Jun binding sites. The distance between
binding sites was less than 25 bp in 96% of these genes, suggesting
that Meq and c-Jun bound as a heterodimer in these regions (see
Fig. S1 in the supplemental material).
To verify if Meq and c-Jun binding sites were concentrated in a
particular portion of the genome, the chicken genome was parti-
tioned into the following categories: promoter (2 kb to TSS), 5=
or 3= untranslated region (UTR), introns, exons, and intergenic
regions. The peaks for Meq and c-Jun binding were significantly
overrepresented in the promoter region (63 and 69%, respec-
tively) and significantly underrepresented (P 0.0001 by 2 test)
in the intergenic region (18 and 13%, respectively) compared to
IgG-bound regions in the chicken genome (10% and 55% in pro-
moter and intergenic regions, respectively) (Fig. 3).
To identify consensus binding motifs in the chicken genome,
the enriched Meq and c-Jun binding sites were analyzed using
MEME (5). The top two candidate motifs that account for 89% of
the Meq binding sites are shown in Web LOGO format (Fig. 4).
Motif 1 had a core sequence that was 97% similar to the previously
described AP-1 consensus binding site (24) as designated by the
JASPAR and TRANSFAC databases (25, 26). Motif 2 had a core
sequence of CACACAGC, which is similar to a putative motif
referred to as MERE-II (14, 24). Analysis of c-Jun binding sites
revealed that an AP-1-like motif was present in 72% of the binding
sites. Next, we analyzed the enriched peaks common to both Meq
FIG 1 ChIP-qPCR validation of a subset of Meq binding sites from ChIP-seq data. Negative-control regions were based on housekeeping genes with no Meq
peaks. Background binding level represents the mean of Meq signals in three negative-control regions. *, P 0.05 compared to IgG.
Subramaniam et al.
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and c-Jun binding sites, which revealed that the top motif in these
common peaks was identical to motif 1, described above. This
corroborates previous evidence that Meq can readily dimerize
with c-Jun and this Meq-Jun heterodimer preferentially binds to
AP-1-like sites (14, 24). Interestingly, motif 2 (MERE-II-like mo-
tif) was not present in the peaks common to both Meq and c-Jun
FIG 2 Distribution of Meq and c-Jun binding sites. (A and B) The distances between Meq (A) and c-Jun (B) binding sites and the nearest TSS within20
kb are shown with the results binned in 1,000-bp intervals. (C and D) A more detailed view of the majority of binding sites that were within2 kb of the
TSS shows the frequency distribution of Meq (C) and c-Jun (D) binding sites in 100-bp intervals. The black dotted line represents a polynomial line of
best fit.
FIG 3 Genomic distribution of Meq binding sites. The chicken genome was
partitioned into five discrete regions, and the relative distribution of Meq and
c-Jun binding sites in these regions is represented (P  0.001 compared to
IgG-bound regions in the chicken genome by the 2 test).
FIG 4 Characterization of Meq DNA binding motifs. Meq binding sites were
examined for commonly occurring motifs using MEME motif analysis soft-
ware. The top two significantly overrepresented motifs within Meq binding
sites are shown. The height of each letter is proportional to its frequency, with
the most frequent base on top.
Genome-Wide Analysis of MDV Meq Regulation
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binding sites, which supports a previous observation that Meq
homodimers bind to the MERE-II motif (14).
To test the relevance of these motifs, Meq-DF-1 cells, which
constitutively express Meq, were transfected with control vector
or luciferase constructs containing repeats of motif 1 or motif 2.
As expected, there was a significant increase in luciferase activity
compared to control with motif 1, suggesting transactivation.
However, there was a decrease in luciferase activity compared to
control vector in the motif 2 luciferase construct, suggesting tran-
scriptional repression (Fig. 5).
Microarray analysis of transcriptional regulation by Meq.
We performed microarray analyses on DF-1 and Meq-DF-1 cell
lines using the Affymetrix Chicken Genome Array, which pro-
vides comprehensive coverage for all annotated chicken genes.
Only genes that showed consistent changes at a statistical signifi-
cance of P values of0.001 were used for further analysis. By this
criterion, there were 236 upregulated genes and 549 downregu-
lated genes in Meq-DF-1 compared to DF-1 (see Table S3 in the
supplemental material).
To further decipher the relationship between DNA binding
by Meq and transcriptional regulation, we integrated ChIP-seq
data in combination with gene expression microarray data.
About 70% of the differentially expressed genes had only Meq
binding sites in their promoters (generated from the list men-
tioned above), indicating a significant and direct role of Meq
binding in regulating gene transcription in Meq-DF-1 cells
(Fig. 6A). Among genes with binding sites for both Meq and
c-Jun in the promoter, 35% of all upregulated genes had bind-
ing sites for both Meq and c-Jun in the promoter compared to
only 10% of all downregulated genes (Fig. 6B).
To further examine the functional categories of genes and po-
tential biologic networks regulated by Meq, we analyzed the list of
differentially expressed genes with Meq-only binding sites, using
Ingenuity Pathway Analysis. The top five cellular pathways en-
riched in this gene list were apoptosis, cell cycle, regulation of
transcription, cell proliferation, and cell migration (Fig. 7A). This
analysis also revealed several important cellular pathways that are
regulated by Meq. For example, 21 of the 95 genes (22%) in the
apoptosis signaling pathway and 31 of the 206 genes in the ERK/
MAPK pathway (15%) were differentially expressed in Meq-DF-1
cells compared to DF-1 cells (Fig. 7B). We validated the microar-
ray findings using RNA from independent experiments from
DF-1 and Meq-DF-1 cells. Eighteen genes from top biological net-
works were used for validation. The fold change using qRT-PCR
was highly correlated with the findings from the microarray data
(r2  0.91; P 0.001) (Fig. 8A and B).
To further analyze the impact of Meq on gene expression, we
employed siRNA to reduce Meq expression. In Meq-DF-1 cells,
Meq-specific siRNA resulted in at least 75% reduction in mRNA
expression (Fig. 9A). qRT-PCR for 4 genes each from our up- and
downregulated gene list was performed in cell lines transfected
with nontargeting siRNA (NT) or siMeq. These results showed
that upon Meq silencing, there was significant attenuation of the
Meq-induced increase in expression of genes that were upregu-
FIG 5 Luciferase reporter assay depicting activity of constructs with either
empty vector (control), repeats of motif 1, or repeats of motif 2. The activity
was normalized to activity in the transfection control (Gaussia luciferase).
Letters (a, b, and c) represent statistically significant differences at P values of
0.05.
FIG 6 Integrated analysis of expression profiling and genome occupancy data. (A) Overlap between genes with Meq binding sites identified by ChIP-seq
experiments and differentially expressed genes based on microarray analysis in Meq-DF-1 cells. (B) Overlap between genes with binding sites common to both
Meq and c-Jun and differential gene expression.
Subramaniam et al.
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lated and of the Meq-dependent decrease in expression of down-
regulated genes (Fig. 9B and C). There was no detectable change in
expression upon siRNA treatment in DF-1 control cells.
Integrated analysis of Meq binding sites and transcriptional
regulation. To determine if the location of Meq binding has any
impact on differential transcriptional regulation, we analyzed the
distribution of Meq binding sites of genes exhibiting up- or down-
regulation. Notably, in upregulated genes (transcriptional activa-
tion), the Meq peaks were located closer to the TSS and concen-
trated more narrowly (Fig. 10A) in comparison to those proximal
to downregulated genes (Fig. 10B). Indeed, about 60% of tran-
scriptionally activated genes contained Meq peaks within 2 kb
around TSS, whereas the same proportion of transcriptionally re-
pressed genes contained peaks within 15 kb. Not surprisingly, up-
regulated genes showed a strong enrichment for Meq binding in
the promoter region (about 70%), whereas the downregulated
FIG 7 Pathway analysis of Meq-regulated genes. (A) Top 5 functional classifications based on canonical pathway analysis of differentially expressed genes with
significant [log (P value) less than 1.3)] Meq binding sites using Ingenuity Pathway Analysis. (B) Overview of ERK/MAPK, Jak-STAT, and ErbB signaling
pathways; the up- and downregulated genes are highlighted in green and red, respectively.
Genome-Wide Analysis of MDV Meq Regulation
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genes had only modest enrichment in the same region (18%). In
contrast, the region with strongest enrichment for Meq binding
sites in downregulated genes was the intergenic region (62%) (Fig.
10C).
To investigate the role of differential binding to motifs and
transcriptional regulation, we analyzed all Meq binding sites from
upregulated and downregulated genes for the presence of these
motifs. We found that motif 1 was overrepresented in upregulated
genes while downregulated genes had a higher incidence of motif
2 (Fig. 11). Indeed, motif 1 was present in 85.6% of upregulated
genes, whereas motif 2 was present in 84.1% of downregulated
genes. We also investigated the possibility of contribution by other
TFs to the ability of Meq to modulate transcription by analyzing
overrepresented sequence motifs within the binding sites. The de-
tails of these TF motifs in up- and downregulated genes along with
relative abundance in differentially expressed genes are shown in
Fig. 11. We found that binding motifs for other bZIP TFs like
CREB1 and NFE2L2 are present in upregulated genes while motifs
for TFs like Myc, BRCA1, and ZEB1 were found mostly in down-
regulated genes, which suggests additional mechanisms for coop-
erativity among TF in regulating gene expression.
Differences in cellular pathways based on the presence of a
certain motif were also examined by testing all genes with motif 1
or motif 2 for overrepresentation in specific canonical pathways.
Among these, the ErbB signaling pathway and VEGF signaling
pathway were common to both motifs. However, there were sig-
naling pathways unique to each motif, as the MAPK, CDK5, and
NF-	B pathways were unique to motif 1 while the death receptor
signaling, Jak-STAT, and telomerase signaling pathways were
unique to motif 2 (Fig. 12A and B).
Functional validation of cellular pathways regulated by Meq:
effect of MAPK inhibitors on cellular proliferation. Assessment
of cell proliferation is a reliable index of the transformative
ability of Meq. Grown under serum-free conditions for 24 h,
Meq-DF-1 cells reached a significantly higher cell number
(25% increase, n  6; P  0.05) than did the parent cell line,
DF-1 (Fig. 13). Furthermore, to assess the biological relevance
of pathway analysis, we used specific inhibitors for some of the
FIG 8 Comparison of gene expression through microarrays and qRT-PCR. (A) Correlation plot comparing differential gene expression using microarray
analysis to qRT-PCR data on a subset of 20 genes in the Meq-DF-1 cell line. (B) qRT-PCR validation of microarray results of the microarray-based differentially
expressed genes between Meq-DF-1 and DF-1 cells. Beta-actin was used as internal control; *, P 0.05 compared to DF-1 cells.
Subramaniam et al.
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targets in top biological networks influenced by Meq expres-
sion. Since the MAPK pathway was the top canonical pathway
overrepresented in the Meq-induced transcriptome, we used
inhibitors to two targets in this pathway. PD 98059, a selective
and potent inhibitor of mitogen-activated protein kinase ki-
nase (MAPKK/MEK), blocked the increase in cell number
noted with Meq-DF-1 cells (Fig. 13). Similarly, inhibition of
another downstream molecule, extracellular signal-regulated
kinase (ERK), using a selective inhibitor, FR 180204, also
blocked the proliferative effect of Meq (Fig. 13). This strongly
supports the role of ERK/MAPK signaling in mediating the
mitogenic effects of Meq.
DISCUSSION
Understanding the mechanisms involved in oncogenesis is essen-
tial to develop long-term strategies to prevent and control MD. A
comprehensive analysis of the target genes induced by its onco-
protein, Meq, is an important first step in unraveling the mecha-
nism of MDV oncogenesis. There is limited information on com-
prehensive genome-wide studies examining the role of the Meq
oncoprotein in transcriptional regulation of host genes. By inte-
grating genome-wide chromatin occupancy data with a compre-
hensive data set of Meq-induced gene expression changes, we have
identified a high-confidence list of Meq target genes by correlating
in vivo occupancy and transcriptional activity in this study. Con-
sequently, these results have the potential to provide fundamental
knowledge into how viral oncoproteins involved in cellular trans-
formation regulate host gene regulatory networks.
ChIP-seq analysis revealed several insights into transcriptional
regulation by Meq. We generated a high-confidence list of genes
that had Meq binding sites in the proximal promoter, and mRNA
expression of 
40% of them was induced or repressed in DF1-
Meq in comparison to DF1. Not all genes with a Meq binding site
were transcriptionally regulated based on our analyses, suggesting
that binding site information alone is an insufficient predictor of
transcriptional regulation. However, among the differentially ex-
pressed genes, about 75% of them had evidence of Meq binding
nearby. In addition, Meq binding to the chicken genome was non-
random, with a strong preference for promoters (within 1 kb up-
stream of the TSS) in the host genome. This result provides strong
evidence that the main biochemical function of Meq is to regulate
transcription.
Analysis of Meq peak locations within genes that were tran-
scriptionally responsive revealed distinct functional consequences
of DNA binding by Meq. Notably, in upregulated genes, the Meq
peaks were located closer to the TSS and a majority of them were
located within 1 kb of their promoters. This suggests that Meq acts
as a transcriptional activator through short-range effects. On the
other hand, Meq peaks in downregulated genes were located
much farther from the TSS, on average, and located mostly in the
intergenic regions. Thus, transcriptional repression by Meq could
involve long-range effects and might involve other corepressor
proteins and more than one mechanism, e.g., those TFs identified
in Fig. 11. Taken together, these findings indicate that the distinct
localization of Meq binding in the chicken genome influences the
nature of transcriptional activity in the host cell. Recent studies on
genome-wide binding site characterization of other transcription
FIG 9 Influence of Meq inhibition through siRNA. (A) Optimization of siRNA concentration and verifying efficiency of knockdown in Meq-DF-1 cells; *, P
0.05 compared to no template (NT) controls. Gene expression changes after siRNA-mediated knockdown of Meq. A selected subset of upregulated (B) and
downregulated (C) genes are shown; *, P 0.05 compared to DF-1 NT; #, P 0.05 compared to Meq-DF-1 NT.
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factors like Myb and PU.1 revealed a similar dependence of the
location of transcription factor binding and its influence on dif-
ferential regulation of transcription (27, 28).
c-Jun has been shown to be an important partner for Meq in
engaging cellular pathways leading to transformation (16).
However, the specific involvement of this partnership in ge-
nome-wide transcriptional regulation in the host has not been
previously reported. We have generated a high-confidence list
of genes that are coregulated by Meq. Colocalization of binding
sites of Meq and c-Jun suggests cooperativity between these
two factors in modulating transcription. A previous study in
human erythroleukemia cells revealed that c-Jun binding sites
were distributed more widely within 100 kb upstream of TSS
(29). Since Meq is highly overexpressed in our model system, it
is possible that the majority of c-Jun is bound with Meq to form
heterodimers, and this may influence the distribution of c-Jun
binding sites that we observed.
Two previously described DNA binding motifs (14, 24) were
confirmed in the Meq-enriched peak regions using position-
weighted matrix analysis and motif discovery tools. Interestingly,
the top motif in the genes that had peaks common to Meq and
c-Jun as well as the top motif among all upregulated genes was
motif 1 (Fig. 11). Previous studies indicate that Meq and c-Jun
form heterodimers and these heterodimers bind to AP-1-like sites,
resulting in transcriptional activation, at least in the context of a
few viral as well as host gene promoters (14, 16, 24). Although we
have not directly tested the possibility of heterodimerization, the
discovery of an AP-1-like motif in genes that bind to both Meq
and c-Jun, as well as in upregulated genes, suggests a similar pos-
sibility. Meq also has the ability to form homodimers with itself.
These homodimers bind to a DNA sequence referred to as
MERE-II and cause transcriptional repression (14). Motif 2 from
our analysis had the core DNA binding sequence described as
MERE-II, and this was the top motif found in all downregulated
genes (Fig. 11). Also, this motif was not discovered in any c-Jun
peaks. Taken together, these findings support the idea of Meq
homodimers binding to this sequence and causing transcriptional
repression.
Both heterodimers and homodimers of Meq have been shown
to be necessary for transformation (30). Analysis of cellular path-
ways in our study suggested that both the AP-1 and MERE-II
motifs (which correspond to hetero- and homodimers, respec-
FIG 10 Differential location of Meq binding sites in up- and downregulated genes. Combination of ChIP-seq data and gene expression analysis reveals a distinct
localization of Meq peaks in up- and downregulated genes. Frequency distribution of Meq binding sites relative to the nearest TSS, represented in 1-kb intervals
for a distance covering 20 kb in upregulated (A) and downregulated (B) genes. (C) Relative occupancy of Meq in genomic regions in upregulated and
downregulated genes (P 0.001 compared to relative distributions in control regions by the 2 test).
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tively) are involved in the regulation of genes involved in key pro-
cesses like cell proliferation, cell cycle, and apoptosis. However,
signaling pathways specific to genes with each motif suggest dis-
tinct binding motif-dependent signatures in gene regulatory net-
works. In other transcription factors like ectopic viral integration
site 1 (EVI1) and PAX6, two DNA binding domains are associated
with distinct motifs and regulate different sets of target genes in-
volved in cellular transformation and development, respectively
(31, 32). It would be interesting to further assess if the het-
erodimers and homodimers of Meq regulate distinct subsets of
genes using modified constructs of Meq as utilized in some previ-
ous studies (30, 33, 34).
The enrichment of Meq target genes for several neoplastic
processes suggests that it probably acts as a multifunctional
transcription factor that modulates multiple processes, includ-
ing cell proliferation, apoptosis/survival, and cell migration.
Some of the previous studies have described a few of the target
genes modulated by Meq, involved in apoptosis and cell pro-
liferation (16). However, there is little information on the reg-
ulatory mechanisms through which Meq affects these features.
FIG 11 Overrepresented motifs in up- and downregulated genes. Comparison of motifs along with sequence logos in up- and downregulated genes and the
percentage of genes with the occurrence of each motif.
FIG 12 Comparative enrichment of cellular pathways in genes with motif 1 (A) and motif 2 (B). Functional classification based on canonical pathway analysis
of differentially expressed genes with significant Meq binding sites using Ingenuity Pathway Analysis. Only the top 5 pathways that reached significance [log (P
value) less than1.3] are shown.
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Our analysis shows that Meq transcriptionally regulates many
genes that are part of several signaling pathways, including the
ERK/MAPK, Jak-STAT, and ErbB pathways, which are critical
for oncogenesis (35–38).
Activation of ERK or MAPK by MEK is an essential event in
mitogenic growth factor signal transduction (39). In our study, we
found that Meq upregulates key players in the pathway like Ras,
MEK1, and MEK2, which initiate downstream signaling leading
to cell proliferation. Other tyrosine kinases like Src were also up-
regulated by Meq. We also found that activating signals upstream
of MAPKs, like ErbB, were upregulated. We have also functionally
validated the relevance of MAPK signaling to the ability of Meq to
transform cells by using specific inhibitors to MEK1/2 and
ERK1/2. These inhibitors abrogated the proliferative effect of
Meq, indicating that key mitogenic signals in the MAPK pathway
are involved in mediating the effects of Meq on cell proliferation.
Our results are in accordance with a proteomic analysis of an
MDV lymphoblastoid cell line, which also indicates that signaling
proteins in the ERK/MAPK pathway are involved in transforma-
tion (40). The activation of Ras/ERK signals is essential for cellular
transformation by LMP1, a major transforming viral oncoprotein
of Epstein-Barr virus, a gammaherpesvirus (41, 42). Furthermore,
LMP1/2 transforms B lymphocytes by providing prosurvival sig-
nals through constitutive phosphorylation of ERK/MAPK and
Ras (43, 44). In addition, several studies implicate the essential
role of ERK/MAPK signaling in maintenance of latency (45),
angiogenesis (46), and cell survival (47, 48) by Kaposi’s sarcoma-
associated herpesvirus. Thus, it would be of interest to further
explore the possibility of convergent cellular signaling networks
by which oncogenic herpesviruses regulate cellular processes and
lead to transformation.
One of the major modes of regulating the MAPK pathway in-
volves restriction of the magnitude and duration of activation
(49). Because MAPKs are fully active only when phosphorylated,
one effective mechanism of MAPK inactivation is dephosphory-
lation by protein phosphatases (50). Interestingly, we found that
Meq downregulated the expression of dual-specificity phosphata-
ses like DUSP4, which inactivates the ERK1/2 family of MAPKs
(51, 52). Dual-specificity phosphatases, also known as MAPK
phosphatases (MKPs), act as a negative regulatory feedback in
modulating MAPK signaling. It has also been proposed that the
integration of multiple MAPK pathways occurs at the level of
MKPs (52). The role of MKPs in cancer is further underlined by
the fact that decreased expression of MKPs is associated with poor
prognosis in various malignancies in humans (53, 54). In addi-
tion, downregulation of serine/threonine phosphatases, including
PP1 and PP2, which target proteins like MEK, Raf, and Akt (51,
55), was also noted. This family of phosphatases act as tumor
suppressor genes that target the ERK/MAPK pathway (56). Sev-
eral viral oncoproteins have been shown to induce transformation
by downregulation of PP2 expression or by inhibiting its activity
(57). PP2 has also been shown to be involved in inhibition of
cyclin E/CDK2 complex (58), which is a key mediator in cell cycle
progression. Taken together, to maintain a proliferative drive, our
work suggests that Meq activates oncogenic signaling cascades by
transcriptionally activating major kinases in the ERK/MAPK
pathway and simultaneously repressing phosphatases. This ability
of Meq appears to be a conserved mechanism of transformation
by viral oncoproteins.
The ability of Meq to upregulate the expression of a mitogenic
signal in a pathway and downregulate the inhibitory signal ap-
pears to be a common strategy across multiple cellular pathways.
For example, we found that a similar phenomenon occurs in the
context of the Jak-STAT signaling pathway as well. We noted that
STAT3, an oncogenic signal, was upregulated while negative reg-
ulators of the pathway like SHP-1, SOCS2, and PIAS were down-
regulated. STAT3 has been reported to be oncogenic in a number
of malignancies in human patients (59–61). In contrast, SHP-1,
SOCS, and PIAS have been shown to act as tumor suppressors
(62–66). SOCS2 is an indispensable negative regulator of growth
hormone (GH) actions (67), and SHP-1 negatively modulates
GH-mediated signal transduction (68). It is interesting that GH is
a putative MD resistance gene (69) and transformation by MDV
involves negative regulation of GH downstream signaling media-
tors.
Another theme that emerges from pathway analysis is the tran-
scriptional regulation of key players that are involved in the regu-
lation of multiple cellular pathways. Meq was noted to transcrip-
tionally activate several members of the 14-3-3 protein family,
which modulate the function of a diverse array of binding partners
and hence function as key regulatory components of many vital
cellular processes (70, 71). Cell cycle deregulation caused by
changes in 14-3-3 expression has been implicated in cancer for-
mation (71). 14-3-3 proteins function at several key points in the
G1/S and G2/M transition by binding to regulatory proteins and
modulating their function (72). In addition, these proteins also
play a major role in regulating the MAPK pathway by contributing
to activation of Raf, leading to cell proliferation (73, 74). Meq also
upregulated Grb2, an adaptor protein, which acts as a critical
downstream intermediary in several oncogenic signaling path-
ways. Grb2 has also been shown to link the ErbB receptor to the
activation of Ras and its downstream kinases, ERK1/2 (75, 76).
Overexpression of Grb2 has been noted in several malignancies,
including breast cancer and bladder cancer (77–79).
Dysregulation of the cellular apoptotic pathway due to a com-
bination of activated antiapoptotic signals and inhibition of pro-
apoptotic signals is one of the hallmarks of cancer (80). We noted
that Meq manipulates several players in the apoptotic pathway to
FIG 13 Functional validation of the role of ERK/MAPK signaling in Meq-
mediated transformation using a cell proliferation assay. MEK or ERK inhib-
itors blocked the proliferative effect of Meq; *, P  0.05 compared to DF-1
control; #, P 0.05 compared to Meq-DF-1 control.
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shift cells toward an antiapoptotic phenotype. We found increased
expression in antiapoptotic signals like Bcl-2 and Bcl-XL with a
subsequent decrease in proapoptotic genes like Bid. Increased ex-
pression of antiapoptotic genes like Bcl-2 and Bcl-XL by MDV has
been well described previously (16, 81, 82). There was a decrease in
expression of caspases 3 and 6, while an increase in expression of
cIAP-1, an inhibitor of caspases, was noted. In MDV-transformed
lymphoblastoid cell lines, a decrease in inhibitor of apoptosis
(IAP) transcript levels was noted with induction of apoptosis (83).
There also was a decrease in expression of AIFM1, a proapoptotic
factor that induces apoptosis in a caspase-independent manner.
Interestingly, we noted a relative downregulation of FOXO1A, an
important transcription factor that regulates gene expression in
response to tumor necrosis factor (TNF)-mediated apoptotic sig-
nals (84). Thus, Meq controls several critical genes involved in
apoptosis to promote transformation.
Taken together, our study using Meq-DF-1 cells as a model
system for MDV-transformed CD4 cells provides novel insights
on the mechanistic basis of how Meq and possibly other viral
proteins that function as oncogenes transform cells and cause
malignancies. In addition, our study provides a comprehensive
analysis of how Meq interacts with host bZIP proteins like
c-Jun to regulate transcription. These data implicate Meq in
the regulation of the cellular ERK/MAPK, Jak-STAT, and
apoptotic pathways to induce transformation, thus suggesting
a novel pathogenicity mechanism for the oncogenicity of
MDV. In addition, this study forms the basis for the selection of
candidate genes’ allelic variation that might be involved in host
genetic resistance to MD.
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Figure S1. Comparative analysis of Meq and c-Jun binding sites. A subset of genes with binding sites common to both 
Meq and c-Jun within 150 bp from the TSS were selected. Within this subset, the distance of binding sites from the 
nearest TSS along with differences between Meq and c-Jun peaks are depicted. The bars represent distance of 
binding site from TSS and the dots represent difference between the peaks.  
Table	  S1.	  List	  of	  primers	  used	  to	  validate	  ChIP	  binding	  peaks.	  
	  
Gene	  
symbol	  	  
Forward	  primer	  	   Reverse	  primer	  
GRB2	   GTGCAGGGTCGTCTCTATTT	   AAGACTGTGGGACACATGATTA	  
SRC	   GCTGTGTATCCTGCCATCTT	   CCAAGGGATCGCTGCTTTAT	  	  
BRCA2	   GGACGTGTATGCAGAGGATTAT	   TCACAGCGCACTGTTCTT	  	  
STAT3	   GGGTAGTGCATCTCCCAAAG	   CAGCCAACTCCAATTCTCCA	  
NRAS	   GGAGGGCGATGACTGAATAC	  	   CACGAAGTGGTTCTGGATGA	  
BCL2	   GGAAGCGTTGCTCAAGTAGAT	   CGGAGATGCACGGCATAAATA	  	  
CASP3	   GAGATGCTGGTTGGTTCTCATA	   GGGCGTAAAGGTAATCCTACAA	  
IKBKB	   TGCGAGGCGCATTGTAAA	   CTTCAGCAAGTTCTTGACTCCT	  
FOXO1	   TTCGCGCTGGAAGACAAA	  	   CGGTTTGTGTGTGTGTTTGG	  
NRG4	   GGAAGCCGCCACCTAAATAA	  	   ATATCTGCCAGGGCAATCAG	  
PARP4	   TTGAGTTTCCGGGTGAGATATG	  	   GATTCCATTTGCACAGCCTAAC	  	  
CXCL12	   GATCAGAGCCAAAGTGGTACAG	   CGTCCCAGCGACAAACAT	  	  
RPAP3	   CCTTAGGAAGGTCCCTTGTATTT	  	   CCAGCTCTCTAATTCCCTCATAAA	  
HAS2	   CCTTCTTACAGGAGTTCGTTCC	  	   TTCTGCCTTCTCCACGTTATG	  
CDH5	   CTTCCAGCTTGTGGGTGTAA	  	   GTTGATCAGCGCAGACTATGA	  
HPRT1	   GTAACCTGCTGCTGCTCTATAA	   AGGCAGAGCAAGAGAACATC	  	  
RPL4	   CATCTCCTGGACTCAAACCTTAG	   CTGTCGCTGAACACTGGATAA	  
LDHA	   CATCTCCTGGACTCAAACCTTAG	  	   CTGTCGCTGAACACTGGATAA	  
	   	  
Table	  S2.	  	  List	  of	  primers	  used	  in	  qRT-­‐PCR	  to	  validate	  differentially	  expressed	  genes.	  
	  
Gene	  
symbol	  	  
Forward	  primer	  	   Reverse	  primer	  
PPP2CB	   TACGTTGCCCTGTCACTGTC	   TCTGGAGACTTCCCACCGAT	  
DUSP4	   CTGCCTGCTGCTGGACTG	   GCCTGACGATGGTGTTGCAG	  
SRC	   TGTCTGTCTGTCTGTGTGCTG	   CTGGCCACAGTGGTACGC	  
MAP2K2	   CCCACCAGACTCCAAGGAAC	   AGATTCTCCCTCTGCCCCAT	  
MAP2K1	   CGGAAAGACTGCAGGGAACT	   TTCTACCAGAGACAGCCCCA	  
GRB2	   ACGGGATATCGAACAGGTGC	   TGGATAAAGTCTCCACGGCG	  
STAT3	   AGTGCTTTCGTGGTGGAGAG	   CTTTGGTGGTGAACTGCACG	  
SOCS2	   GTACCAGGACGGCAAGTTCA	   GCTGTTGAACTGCTTGAGCC	  
SOCS1	   CCCACCAGCATCCGGATAAA	   ATACCTTCCTCGGGGAGCTT	  
PTPN6	   GGCTGGAAGCTGAAGCCTTA	   TTCTTTCGACTGGGTCTGGC	  
PTPN11	   GATGGCAGTTTTCTGGCACG	   GCTCCAGTTCGCCTAACAGA	  
PIAS1	   CTCTCCAGCGTACACCCAAG	   GGCCATCGTAACTGAGCTGT	  
BCL2L1	   CAGGAGCTGCTAAGTGTGCT	   CCCGGTTACTGCTGGACATT	  
BCL2	   TTCCGTGATGGGGTCAACTG	   GTGGCAATGTTGTCCACCAG	  
BIRC2	   AAGGCTGTTTTGTTCCGCAC	   TAAGTCCCGTTTGAGGTGCC	  
CASP3	   CCTGCTAGCAAGTCTGTGGA	   TCCGGTATCTCGGTGGAAGT	  
CASP6	   ATGCAGCTGGCGTCTATACC	   CTTGGATGTACCAGGAGCCG	  
FOXO1	   TCCCCCAGTGTGATAGTGGT	   TTTTGGCCGTAAAAGCAGGC	  
	  
